Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension
An 8-week, Double-blind, Randomized, Parallel Group, Multi-center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Amlodipine 10 mg Compared to Amlodipine 10 mg in Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Investigative Site
-
-
-
-
-
Manilla, Philippines
- Investigative Site
-
-
-
-
-
Bucharest, Romania
- Investigative Site
-
-
-
-
-
Moscow, Russian Federation
- Investigative Site
-
-
-
-
-
Singapore, Singapore
- Investigative Site
-
-
-
-
-
Madrid, Spain
- Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients ≥ 18 years of age
- Patients with a diagnosis of moderate to severe hypertension, defined as msSBP ≥ 160 mmHg and < 200 mmHg at Visit 2
Exclusion Criteria:
- Mild to moderate hypertension
- Pregnant or nursing (lactating) women
- Women of child-bearing potential
- Previous or current diagnosis of heart failure New York Heart Association(NYHA) Class II-IV.
- Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1.
- Uncontrolled Type 1 or Type 2 diabetes mellitus
- Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures
- History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention
- Patients on a combination of 3 or more antihypertensive medications
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Aliskiren/amlodipine 300/10 mg tablet
Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week.
For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
|
Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed.
In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
|
|
Active Comparator: Amlodipine 10 mg capsule
Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week.
For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
|
Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed.
In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Sitting Systolic Blood Pressure (msSBP)
Time Frame: Baseline to end of study (Week 8)
|
Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)
|
Baseline to end of study (Week 8)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Sitting Diastolic Blood Pressure (msDBP)
Time Frame: Baseline to end of study (Week 8)
|
Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)
|
Baseline to end of study (Week 8)
|
|
Systolic Blood Pressure Response
Time Frame: Baseline to end of study (Week 8)
|
Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP < 140 mmHg or a reduction => 20 mmHg from the baseline) from baseline to end of study (Week 8)
|
Baseline to end of study (Week 8)
|
|
Diastolic Blood Pressure Response
Time Frame: Baseline to end of study (Week 8)
|
Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP < 90 mmHg or a reduction ≥ 10 mmHg from the baseline) from baseline to end of study (Week 8)
|
Baseline to end of study (Week 8)
|
|
Blood Pressure Control
Time Frame: End of study (Week 8)
|
Percentage of patients achieving blood pressure control (msSBP < 140 mm Hg and msDBP < 90 mm Hg) at end of study
|
End of study (Week 8)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CSPA100A2306
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.